User profiles for "author:Mohamed Ghaith Al-Kuwari"

Mohamed Ghaith Al-Kuwari

Sr. Consultant , Preventive Medicine, PHCC
Verified email at phcc.gov.qa
Cited by 7520

[HTML][HTML] Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar

LJ Abu-Raddad, H Chemaitelly… - … England Journal of …, 2022 - Mass Medical Soc
Background Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and
the emergence of the omicron (or B. 1.1. 529) variant of the severe acute respiratory …

[HTML][HTML] mRNA-1273 COVID-19 vaccine effectiveness against the B. 1.1. 7 and B. 1.351 variants and severe COVID-19 disease in Qatar

H Chemaitelly, HM Yassine, FM Benslimane… - Nature medicine, 2021 - nature.com
The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273
(Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic …

[HTML][HTML] Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA. 1 and BA. 2 subvariants in Qatar

H Chemaitelly, HH Ayoub, S AlMukdad, P Coyle… - Nature …, 2022 - nature.com
Abstract SARS-CoV-2 Omicron BA. 1 and BA. 2 subvariants are genetically divergent. We
conducted a matched, test-negative, case-control study to estimate duration of protection of …

[HTML][HTML] BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

P Tang, MR Hasan, H Chemaitelly, HM Yassine… - Nature medicine, 2021 - nature.com
With the global expansion of the highly transmissible SARS-CoV-2 Delta (B. 1.617. 2)
variant, we conducted a matched test-negative case–control study to assess the real-world …

[HTML][HTML] SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy

LJ Abu-Raddad, H Chemaitelly, P Coyle… - …, 2021 - thelancet.com
Background Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) has been documented, raising public health concerns. SARS-CoV-2 reinfections …

Duration of immune protection of SARS-CoV-2 natural infection against reinfection

H Chemaitelly, N Nagelkerke, HH Ayoub… - Journal of Travel …, 2022 - academic.oup.com
Background The future of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) pandemic hinges on virus evolution and duration of immune protection of natural infection …

Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar

LJ Abu-Raddad, H Chemaitelly, HH Ayoub… - Jama, 2021 - jamanetwork.com
Importance The effect of prior SARS-CoV-2 infection on vaccine protection remains poorly
understood. Objective To assess protection from SARS-CoV-2 breakthrough infection after …

[HTML][HTML] Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study

H Chemaitelly, HH Ayoub, P Tang, P Coyle… - The Lancet Infectious …, 2023 - thelancet.com
Background Long-term effectiveness of COVID-19 mRNA boosters in populations with
different previous infection histories and clinical vulnerability profiles is inadequately …

[HTML][HTML] Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective …

H Chemaitelly, HH Ayoub, S AlMukdad, P Coyle… - The Lancet …, 2022 - thelancet.com
Background Understanding protection conferred by natural SARS-CoV-2 infection versus
COVID-19 vaccination is important for informing vaccine mandate decisions. We compared …

[HTML][HTML] Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections

LJ Abu-Raddad, H Chemaitelly, HH Ayoub… - Nature …, 2022 - nature.com
SARS-CoV-2 breakthrough infections in vaccinated individuals and in those who had a prior
infection have been observed globally, but the transmission potential of these infections is …